White House: HHS has sufficient cybersecurity regulations

The Department of Health and Human Services (HHS) need not issue any more regulations governing cybersecurity.

The “administration has determined that existing regulatory requirements, when complemented with strong voluntary partnerships, are capable of mitigating cyber risks to our critical systems and information,” according to a blog post from White House Cybersecurity Coordinator Michael Daniel.

Other agencies not required to issue additional regulations include the Department of Homeland Security and the Environmental Protection Agency.

In February 2013, a presidential executive order required agencies to determine whether existing regulations were sufficient and could be better aligned with the National Institute of Standards and Technology’s cybersecurity framework issued earlier this year. The HHS had determined that its regulatory requirements were adequate.

While the White House agreed more regulations are unneeded, Daniel stressed that cybersecurity efforts are ongoing.

"This doesn’t mean that we don’t have more work to do to secure our critical systems and information throughout the country. Nor does it mean that we can stop working to ensure that regulations as written are clear, streamlined and harmonized. It does mean that agencies with regulatory authority have determined that existing regulatory requirements, when complemented with strong voluntary partnerships, are capable of mitigating cyber risks to those systems," Daniel wrote. "Over the next two years, these departments and agencies will jointly investigate and leverage opportunities to improve the efficiency, clarity and coordination of existing regulations."

Read the blog post here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.